ATE409029T1 - Verwendung von mitoguazon dihydrochlorid zur behandlung von makrophagen-assoziierten erkrankungen - Google Patents

Verwendung von mitoguazon dihydrochlorid zur behandlung von makrophagen-assoziierten erkrankungen

Info

Publication number
ATE409029T1
ATE409029T1 AT98955140T AT98955140T ATE409029T1 AT E409029 T1 ATE409029 T1 AT E409029T1 AT 98955140 T AT98955140 T AT 98955140T AT 98955140 T AT98955140 T AT 98955140T AT E409029 T1 ATE409029 T1 AT E409029T1
Authority
AT
Austria
Prior art keywords
macrophage
disease
hiv
alzheimer
methods
Prior art date
Application number
AT98955140T
Other languages
English (en)
Inventor
Michael Mcgrath
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE409029T1 publication Critical patent/ATE409029T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
AT98955140T 1997-10-27 1998-10-27 Verwendung von mitoguazon dihydrochlorid zur behandlung von makrophagen-assoziierten erkrankungen ATE409029T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6331797P 1997-10-27 1997-10-27
US6331897P 1997-10-27 1997-10-27
US09/179,383 US7087648B1 (en) 1997-10-27 1998-10-26 Methods for modulating macrophage proliferation using polyamine analogs

Publications (1)

Publication Number Publication Date
ATE409029T1 true ATE409029T1 (de) 2008-10-15

Family

ID=27370455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955140T ATE409029T1 (de) 1997-10-27 1998-10-27 Verwendung von mitoguazon dihydrochlorid zur behandlung von makrophagen-assoziierten erkrankungen

Country Status (8)

Country Link
US (3) US7087648B1 (de)
EP (1) EP1027040B1 (de)
JP (1) JP2001520990A (de)
AT (1) ATE409029T1 (de)
AU (1) AU760546C (de)
CA (1) CA2308274C (de)
DE (1) DE69840048D1 (de)
WO (1) WO1999021542A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
JP2002543163A (ja) * 1999-04-30 2002-12-17 スリル バイオメディカル コーポレイション 癌および前立腺疾患のための治療としての結合体
AU4679900A (en) 1999-04-30 2000-11-17 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
FR2802817B1 (fr) * 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
EP1448183A2 (de) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Behandlung von neurodegenerativen erkrankungen durch modulieren des polyaminenbiosynthesewegs
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
EP1453787A1 (de) 2001-12-07 2004-09-08 SLIL Biomedical Corporation Zykloalkyl-substituierte polyamine zur krebstherapie und verfahren zur deren herstellung
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
CA2623203C (en) * 2005-09-23 2014-08-12 Pathologica, Llc Methods for treating viral infections using polyamine analogs
WO2007106554A2 (en) * 2006-03-14 2007-09-20 Progen Pharmaceuticals, Inc. Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
EP2054058B1 (de) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
US20110091418A1 (en) * 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
EP2121586B1 (de) * 2007-03-09 2017-03-08 Pathologica LLC Mgbg zur osteopontin-regelung und behandlung von multipler sklerose
NZ628513A (en) * 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
EP2563761A1 (de) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Aktivatoren der menschlichen pyruvatkinase
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
WO2012112245A1 (en) 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN104011210B (zh) 2011-10-11 2018-05-01 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
EP3831372A1 (de) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazon zur verhinderung des rückfalls oder des fortschreitens der multiplen sklerose
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
MX2018004674A (es) 2015-10-23 2018-09-11 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
EP3389664A4 (de) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Koffeininhibitoren von mthfd2 und verwendungen dafür
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3426243B1 (de) 2016-03-09 2021-05-19 Raze Therapeutics, Inc. 3-phosphoglycerat-dehydrogenase-inhibitoren und verwendungen davon
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
AU2018258355B2 (en) 2017-04-26 2024-05-30 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
RU2020112854A (ru) 2017-11-30 2021-12-30 Арракис Терапьютикс, Инк. Фотозонды, связывающие нуклеиновые кислоты, и способы их применения
DK3813946T3 (da) 2018-06-15 2024-08-19 Janssen Pharmaceutica Nv Rapamycin-analoger og anvendelser deraf
EP3870158A4 (de) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Polymorphe verbindungen und verwendungen davon
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
JPS606348A (ja) 1983-06-09 1985-01-14 ケルベル・アクチエンゲゼルシヤフト 回転研削工具の支承装置
NZ212053A (en) 1984-05-17 1988-02-29 Merrell Dow Pharma Polyamine containing pharmaceutical compositions for treating neoplasms
US5091576A (en) * 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5342945A (en) 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
NZ223340A (en) 1987-02-03 1991-03-26 Merrell Dow Pharma Polyamine derivatives and pharmaceutical compositions
US4847257A (en) 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
ZA903804B (en) 1989-05-23 1991-03-27 Merrell Dow Pharma A method of potentiating cell-mediated immunity utilizing polyamine derivatives
EP0415801A1 (de) 1989-07-05 1991-03-06 N.V. Innogenetics S.A. Monoklonale Antikörper gegen aktivierte Mikrogliazellen
US5037846A (en) 1990-01-02 1991-08-06 Pfizer Inc. Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters
AU1372692A (en) 1991-02-08 1992-09-07 Immunex Corporation Method of inhibiting replication of hiv in macrophages
CZ39994A3 (en) 1991-08-23 1994-11-16 Pfizer Synthetic aryl polyamines representing antagonists of excitation amino acid neurotransmitters, process of their preparation and use
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
AU3609893A (en) 1992-01-29 1993-09-01 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
CA2094341A1 (en) 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
US5460807A (en) 1992-08-19 1995-10-24 Merrell Dow Pharmaceuticals Inc. Antiproliferative oligomers
US5672746A (en) 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5665588A (en) 1993-09-24 1997-09-09 Univ Arkansas DNA encoding natural killer lytic associated protein
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5516807A (en) 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
JPH08217670A (ja) 1995-02-14 1996-08-27 Meiji Seika Kaisha Ltd 脳機能改善剤
US5677350A (en) 1995-06-07 1997-10-14 Wisconsin Alumni Research Foundation Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes
US5886051A (en) 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ES2175400T3 (es) 1996-03-06 2002-11-16 Schulz Jorg Prof Dr Med Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.
US5906996A (en) * 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
DE69711413T2 (de) 1996-10-18 2002-07-18 Wisconsin Alumni Research Foundation, Madison In ihrer konformation eingeschränkte polyamine und ihre verwendung als antineoplastische mittel
AU758570B2 (en) * 1997-07-15 2003-03-27 Mediquest Therapeutics, Inc. Novel polyamine analogues as therapeutic and diagnostic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
CA2623203C (en) * 2005-09-23 2014-08-12 Pathologica, Llc Methods for treating viral infections using polyamine analogs

Also Published As

Publication number Publication date
EP1027040A2 (de) 2000-08-16
CA2308274A1 (en) 1999-05-06
EP1027040B1 (de) 2008-09-24
US8008353B2 (en) 2011-08-30
AU760546B2 (en) 2003-05-15
US7087648B1 (en) 2006-08-08
JP2001520990A (ja) 2001-11-06
WO1999021542A2 (en) 1999-05-06
WO1999021542A3 (en) 2000-01-20
AU1201899A (en) 1999-05-17
CA2308274C (en) 2010-02-09
US20120022166A1 (en) 2012-01-26
DE69840048D1 (de) 2008-11-06
AU760546C (en) 2006-03-30
US20050159493A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE409029T1 (de) Verwendung von mitoguazon dihydrochlorid zur behandlung von makrophagen-assoziierten erkrankungen
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
EP1474687A4 (de) Marks als modifikatoren des p53-pfades und anwendungsverfahren
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
CY1104988T1 (el) Μεθοδος αντιμετωπισης μολυνσεων του μεσου ωτος
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
BR0312217A (pt) Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
ATE311876T1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
NO20004419D0 (no) Ny anvendelse
ATE208384T1 (de) Verwendung von ascorbyl-gamma-linolenat und von ascorbyl-dihomo-gamma-linolenat zur behandlung von asthma, krebs, kardiovaskulären und inflammatorischen erkrankungen
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
NO179472C (no) Opplösning omfattende benzoxoniumklorid for behandling av kontaktlinser, og anvendelse derav til konservering av kontaktlinser og legemidler for öynene
BR0314541A (pt) Tratamento de demência e doença de parkinson
DE69920959D1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
TR199901385T2 (xx) Piperidin t�revleri.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties